18FDG-PET applications for cartilage neoplasms

Skeletal Radiol. 2005 Jul;34(7):367-74. doi: 10.1007/s00256-005-0894-y. Epub 2005 Jun 4.

Abstract

Objective: To assess the value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography (18FDG-PET) in defining aggressive cartilage neoplasms, particularly those with problematic or borderline histologic, imaging and clinical characteristics.

Design and patients: From 2000 to 2003, 29 cartilage lesions were studied with whole-body 18FDG-PET scans (Siemens Ecat Exact, Knoxville, Tenn.). Analyses of data in 20 females and nine males, 11-85 years old, were based on maximum standard uptake values (SUVs) in regions of interest (ROIs) on axial 3.37 mm thick, 3x3 pixel images. A statistically significant maximum SUV cutoff of 2.0 was used to distinguish benign from malignant cartilage neoplasms and correlated with the postoperative histopathologic findings.

Results: In 26 operated cases the overall sensitivity of whole-body 18FDG-PET in separating benign and malignant lesions was 90.9% (10/11), specificity 100% (18/18) and accuracy 96.6%.

Conclusions: Whole-body 18FDG-PET is a valuable adjunct in identifying primary, recurrent and metastatic cartilage malignancies. It supplements classic histology and morphologic imaging with functional data which may facilitate management in individual cases.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Neoplasms / diagnostic imaging*
  • Cartilage Diseases / diagnostic imaging*
  • Child
  • Chondroma / diagnostic imaging
  • Chondrosarcoma / diagnostic imaging
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Male
  • Middle Aged
  • Osteochondroma / diagnostic imaging
  • Positron-Emission Tomography*
  • Radiopharmaceuticals*
  • Sensitivity and Specificity

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18